Log in

Relevant bibliographies by topics / Hypertension – Treatment

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Hypertension – Treatment'

Author: Grafiati

Published: 4 June 2021

Last updated: 21 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hypertension – Treatment.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Hypertension – Treatment"

1

Sica, Domenic A. "Hypertension Treatment." Hypertension 50, no. 2 (August 2007): 287–88. http://dx.doi.org/10.1161/hypertensionaha.107.092114.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Dustan, Harriet P. "Hypertension Treatment." Archives of Internal Medicine 156, no. 17 (September 23, 1996): 1913. http://dx.doi.org/10.1001/archinte.1996.00440160013002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Shimamoto, Kazuaki. "Hypertension treatment for elderly hypertension." Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 40, no. 3 (2003): 213–15. http://dx.doi.org/10.3143/geriatrics.40.213.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

ARAKAWA, KIKUO. "Hypertension : progress in diagnosis and treatment. Treatment. General treatment of hypertension." Nihon Naika Gakkai Zasshi 79, no. 1 (1990): 33–37. http://dx.doi.org/10.2169/naika.79.33.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Zanchetti, Alberto. "Challenges of hypertension and hypertension treatment." Journal of Hypertension 32, no. 10 (October 2014): 1917–18. http://dx.doi.org/10.1097/hjh.0000000000000359.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mushtaq, Ayesha. "The Nutrition Therapy, Treatment, Pathophysiology, Etiology, Epidemiology of Hypertension." Journal of Food and Nutrition 1, no. 2 (December 7, 2022): 01–04. http://dx.doi.org/10.58489/2836-2276/008.

Full text

Abstract:

Hypertension is both a cardiovascular condition and risk factor for other forms of cardiovascular disease. An increase in BP increases the forces applied to the endothelium and can cause initiation of an atherosclerotic lesion. Changes in pressure may also cause established plaques to rupture, which not only can initiate an event such as an infarct but also cause a proliferation of existing plaques. From 40 to 70 years of age, an increase of systolic BP by 20 mmHg increases risk of CVD in systolic blood pressure of hypertensive will prevent one death for every 11 patients treated. Basically, hypertension is a condition of chronically elevated blood pressure. Nutrition treatment of hypertension include lifestyle modification in which nutrition therapy, physical activity, ideal BMI, weight loss goals are added to prevent the more risk. Furthermore, the DASH is used to approach the nutrition therapy for hypertension. Minerals are added to diet to treat the hypertension i.e., potassium, calcium magnesium have all been positively correlated with reduction of BP and treatment of hypertension. It is important to remember that the nutritional effects demonstrated by the DASH study and in particular the relationship between K, Ca, Mg and blood pressure reduction were a result of a dietary pattern rich in these nutrients rather than mineral intake from supplements.

APA, Harvard, Vancouver, ISO, and other styles

7

&NA;. "Hypertension treatment recommendations." Inpharma Weekly &NA;, no. 1198 (July 1999): 2. http://dx.doi.org/10.2165/00128413-199911980-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Takahashi, Atsuhiko, and Toshio Kushiro. "Hypertension treatment guidelines." Health Evaluation and Promotion 39, no. 2 (2012): 285–94. http://dx.doi.org/10.7143/jhep.39.285.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Milošević, Maja, and Petar Otašević. "Treatment-resistant hypertension." Arhiv za farmaciju 72, no. 1 (2022): 1–19. http://dx.doi.org/10.5937/arhfarm72-34248.

Full text

Abstract:

Treatment-resistant hypertension is one of the most significant causes of poor blood pressure regulation. Patients with resistant hypertension are at a higher risk of developing comorbidities compared to the general hypertensive population. As a result, these patients have an increased incidence of disability and premature death, as well as increased treatment costs. Due to the above-mentioned, in the last decade, there has been an increase in researchers' interest in elucidating the pathogenesis, diagnosis, and treatment of resistant hypertension. However, recent data indicate that 20% of female and 24% of male patients with arterial hypertension still have uncontrolled blood pressure, despite maximum doses of three antihypertensive drugs (including a diuretic) and appropriate lifestyle measures. New treatment modalities (i.e. devicebased interventions - catheter-based renal denervation and baroreceptor stimulation) offer hope for achieving adequate blood pressure regulation in these patients. In this paper, we have summarized previous knowledge about the mechanisms underlying the pathogenesis of resistant hypertension, as well as optimal diagnostic methods to differentiate true from pseudo-resistant hypertension. We have also given an overview of the current therapeutic approach, including optimal medical therapy and new treatment modalities (i.e. device-based interventions) and their role in the treatment of resistant hypertension.

APA, Harvard, Vancouver, ISO, and other styles

10

Dustan, Harriet P. "Treatment of Hypertension." Southern Medical Journal 90, Supplement (December 1997): 1. http://dx.doi.org/10.1097/00007611-199712001-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Hypertension – Treatment"

1

Kalra, Lalit. "The effects of hypertension and hypertensive treatment on psychomotor performance." Thesis, King's College London (University of London), 1991. https://kclpure.kcl.ac.uk/portal/en/theses/the-effects-of-hypertension-and-hypertensive-treatment-on-psychomotor-performance(724a49ad-9e80-4a77-9a76-357cd0f6e277).html.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Epstein, Christina (Christina Lynn). "An analytics approach to hypertension treatment." Thesis, Massachusetts Institute of Technology, 2014. http://hdl.handle.net/1721.1/91299.

Full text

Abstract:

Thesis: S.M., Massachusetts Institute of Technology, Sloan School of Management, Operations Research Center, 2014.
This electronic version was submitted by the student author. The certified thesis is available in the Institute Archives and Special Collections.
13
Cataloged from student-submitted PDF version of thesis.
Includes bibliographical references (pages 67-68).
Hypertension is a major public health issue worldwide, affecting more than a third of the adult population and increasing the risk of myocardial infarction, heart failure, stroke, and kidney disease. Current clinical guidelines have yet to achieve consensus and continue to rely on expert opinion for recommendations lacking a sufficient evidence base. In practice, trial and error is typically required to discover a medication combination and dosage that works to control blood pressure for a given patient. We propose an analytics approach to hypertension treatment: applying visualization, predictive analytics methods, and optimization to existing electronic health record data to (1) find conjectures parallel and potentially orthogonal to guidelines, (2) hasten response time to therapy, and/or (3) optimize therapy selection. This thesis presents work toward these goals including data preprocessing and exploration, feature creation, the discovery of clinically-relevant clusters based on select blood pressure features, and three development spirals of predictive models and results.
by Christina Epstein.
S.M.

APA, Harvard, Vancouver, ISO, and other styles

3

Ali, Omar Farhan. "Statins as a treatment for pulmonary hypertension." Thesis, Imperial College London, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.521123.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Francis, Bahaa. "Pharmacological treatment with tetrahydrobiopterin in pulmonary hypertension." Thesis, Imperial College London, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.530471.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Hallberg, Pär. "Pharmacogenomics of antihypertensive treatment & clinical pharmacological studies of digoxin treatment /." Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5782.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Welsh, Tomas J. "The treatment of hypertension in people with dementia." Thesis, University of Nottingham, 2016. http://eprints.nottingham.ac.uk/33468/.

Full text

Abstract:

Introduction: Current guidance on the treatment of high blood pressure provides the advice that co-pathology should be taken into account when treatment decisions are made, but does not specify the approach in people with dementia. A relationship between high blood pressure and dementia, all be it complex and variable over time, does exist, making dementia a relevant co-pathology in decisions around the treatment of hypertension. No trial evidence exists however to guide clinical decision making in this specific context and clinicians with theoretical concerns over adverse events or varying priorities may act differently while remaining within the scope of current guidance. To inform the design of potential future research examining the repercussions of different treatment approaches, the way high blood pressure is currently treated in people with dementia and the adverse events they experience need to be understood. Aims: This thesis reports research which set out to describe the treatment of high blood pressure in people with dementia and the adverse events that this population experienced over a six month period. Methods: (i) A systematic literature review of observational studies describing the treatment of hypertension in people with dementia was performed. (ii) A multicentre cohort study, the Hypertension IN Dementia (HIND) study, of 181 participants, recorded information on dependency in activities of daily living (ADLs), cognition, medication, diagnoses, and healthcare use. It provided a detailed description of the treatment of high blood pressure in the study population and the adverse events experienced over a 6 month period. Results: Literature review: The prevalence of hypertension in people with dementia was 45% (range 36%-84%), of whom 73% (range 48%-85%) were taking at least one antihypertensive. 55% of people with dementia achieved target blood pressure in the one study that reported this. The review found no studies that specifically set out to describe the treatment of high blood pressure in people with dementia in the UK. Cohort study: 181 participants were recruited from general practices and via memory clinics. The rate of recruitment was low (8%) in the GP arm, resulting in potential selection bias. The study population were mildly cognitively impaired (median MMSE 23 (IQR 18-26)), 56% were dependent for at least one ADL, had a median of 5 (IQR 3-7) diagnoses and were treated with a median of 7 (5-9) medications. High blood pressure was treated in 87% (95% CI 82% - 92%) and target blood pressure was achieved in 57% (95% CI 49% - 64%) of those on treatment, no different from the general population (87% (95% CI 85% - 89%) treated and 52% (95% CI 49% - 55%) achieving target). ACEi/ARBs were the most frequently prescribed antihypertensive class (55%), followed by calcium channel blockers (33%), beta-blockers (30%) and diuretics (21%). Diuretics were less likely to be prescribed than in the general population (21% (95% CI 15%-26%) vs 34% (95% CI 31% - 37%)). During 6 months follow up the study population reported 475 GP appointments, 65 hospital admissions, 214 falls, 1 myocardial infarction, 6 strokes and 8 deaths. Heart failure, stroke, recurrent falls, falls with fractures, death and GP appointments were more common in the study population than in benchmark populations. Conclusion: In conclusion in an area where clinicians were acting without a firm evidence base and where there were theoretical concerns around the potential side effects of antihypertensive use, clinicians treated hypertension in people with dementia much as they did in people without dementia. The same classes of antihypertensives were used to maintain blood pressure at a similar level to that achievable in the general population. Despite a potential selection bias that may have over recruited fitter and milder people with dementia than the overall population, the study population reported a higher level of cardiovascular events, recurrent falls, fractures and adverse symptomatology than those without dementia in benchmark populations. Although this finding could relate to reporting bias or a higher intrinsic cardiovascular risk it raises the possibility that the benefits of antihypertensive treatment are attenuated, while the risks are increased, in people with dementia with implications for the risk-benefit ratio in this population. Future specific research, using an approach that avoids selection bias, to explore the risk-benefit ratio of antihypertensive treatment in people with dementia is outlined and advice is provided to clinicians managing high blood pressure in people with dementia.

APA, Harvard, Vancouver, ISO, and other styles

7

Marriott, Helen Maria. "Pulmonary hypertension : susceptibility and treatment in rat models." Thesis, University of Sheffield, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.246988.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Arigoni, Chiara. "Acute treatment of arterial hypertension with calcium antagonists /." [S.l : s.n.], 1986. http://www.ub.unibe.ch/content/bibliotheken_sammlungen/sondersammlungen/dissen_bestellformular/index_ger.html.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Persson, Mats. "Bring hypertension guidelines into play : guideline-based decision support system for drug treatment of hypertension and epidemiological aspects of hypertension guidelines." Doctoral thesis, Umeå universitet, Allmänmedicin, 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-94105.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Suen, Colin. "Novel Therapeutic Strategies for the Treatment of Pulmonary Arterial Hypertension." Thesis, Université d'Ottawa / University of Ottawa, 2017. http://hdl.handle.net/10393/36242.

Full text

Abstract:

Pulmonary arterial hypertension (PAH) is a progressive disease that results in increased pulmonary vasculature resistance, causing right ventricular (RV) remodeling, which eventually progresses into right heart failure and mortality. New and emerging therapeutic strategies involve regenerative approaches to repair the underlying vascular pathology using regenerative cell therapy and methods to alleviate RV dysfunction in the setting of fixed RV afterload. In the first section of the thesis, we investigated the role of EPC paracrine mechanisms in the treatment of PAH. We characterized the paracrine function of EPCs by demonstrating that EPC conditioned medium enhances endothelial cell migration, survival and angiogenesis in vitro. We further examined the role of secreted extracellular vesicles in the paracrine function of EPCs, which played a minor role in promoting wound healing. However, using the monocrotaline rat model of PAH, we did not demonstrate a consistent benefit on RV pressures or remodeling with EPCs or EPC conditioned medium. The lack of effect may be related to the advanced phenotype observed in our model of PAH. Survival in severe pulmonary arterial hypertension (PAH) is related to the ability of the right ventricle (RV) to adapt to increased afterload. Therefore, we explored the effect of genetic background on right ventricular adaptation and survival in a rat model of severe (PAH). Compared to the conventional Sprague-Dawley rat strain, we observed high mortality in the Fischer SUHx model of severe PAH. This was related to a strain-dependent failure of RV adaptation, as evidenced by RV dilatation, RV contractile dysfunction, decreased cardiac ouptut and decreased exercise capacity. Further analysis by gene expression microarrays and fluorescence microangiography demonstrate that failure of RV adaptation is due at least in part due to lack of adequate microvascular angiogenesis in the hypertrophied RV. This work lays the foundation for the section on RV-specific therapy that follows. Using the Fischer model of maladaptive RV remodeling, we tested whether cardiotrophin-1 (CT-1), a pro-angiogenic and cardioprotective cytokine, could improve RV adaptation. We demonstrated that as a rescue treatment, CT-1 reduced RV dilatation and function without influencing RV afterload, which suggests improved RV adaptation. These changes were associated with an increase in RV capillary density. As an early-stage preventative treatment, in addition to improving RV remodeling, CT-1 also reduced pulmonary pressures. These hemodynamic changes suggest that CT-1 may also have a direct impact on vascular tone or the underlying pulmonary vascular pathology.

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Hypertension – Treatment"

1

Hypertension: Evaluation and treatment. Baltimore, Md: Williams & Wilkins, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Madden, Brendan, ed. Treatment of Pulmonary Hypertension. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-13581-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Messerli, Franz H. Clinician’s Manual: Treatment of Hypertension. Tarporley: Springer Healthcare Ltd., 2011. http://dx.doi.org/10.1007/978-1-907673-32-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Jaime, Bosch, ed. Portal hypertension: Pathophysiology and treatment. Oxford: Blackwell Scientific, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

service), SpringerLink (Online, ed. Clinician’s Manual: Treatment of Hypertension. Tarporley: Springer Healthcare Ltd., 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Kenneth, Weir E., Archer Stephen L, and Reeves John T, eds. The Diagnosis and treatment of pulmonary hypertension. Mount Kisco, NY: Futura Pub. Co., 1992.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

1931-, Kaplan Norman M., and Ram C. Venkata S, eds. Individualized therapy of hypertension. New York: M. Dekker, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

CV. Gao xie ya de ju jia liao fa. Hong Kong: Wan Yuan, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Gao xue ya de ju jia liao fa. Taibei Shi: Nuan liu chu ban she, 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Laplante, Louis. Hypertension: The therapeutic alliance. 2nd ed. Montréal: Grosvenor House Press, 1994.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Hypertension – Treatment"

1

De Franchis, R., and M. Primignani. "Endoscopic Treatment." In Portal Hypertension, 159–75. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-642-57116-9_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Malchoff, Carl D., Dougald MacGillivray, and Steven Shichman. "Pheochromocytoma Treatment." In Secondary Hypertension, 235–49. Totowa, NJ: Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-757-4_14.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Lorimer, A. Ross, and W. Stewart Hillis. "Hypertension." In Treatment in Clinical Medicine, 175–218. London: Springer London, 1985. http://dx.doi.org/10.1007/978-1-4471-3120-5_10.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Staessen, J., R. Fagard, P. Lijnen, R. Van Hoof, and A. Amery. "Indications for Antihypertensive Treatment." In Primary Hypertension, 153–62. Berlin, Heidelberg: Springer Berlin Heidelberg, 1986. http://dx.doi.org/10.1007/978-3-642-71125-1_15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Daniels, Stephen R., and Sarah C. Couch. "Nonpharmacologic Treatment of Pediatric Hypertension." In Pediatric Hypertension, 755–66. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-31107-4_35.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Ferguson, Michael A. "Pharmacologic Treatment of Pediatric Hypertension." In Pediatric Hypertension, 767–90. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-31107-4_36.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Daniels, Stephen R., and Sarah C. Couch. "Nonpharmacologic Treatment of Pediatric Hypertension." In Pediatric Hypertension, 1–12. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-31420-4_35-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ferguson, Michael A. "Pharmacologic Treatment of Pediatric Hypertension." In Pediatric Hypertension, 1–25. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-31420-4_36-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Collins, R. Thomas, and Bruce S. Alpert. "Nonpharmacologic Treatment of Pediatric Hypertension." In Pediatric Hypertension, 529–35. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60327-824-9_30.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Alpert, Bruce S., Michael Hasselle, and Sidney Ornduff. "Nonpharmacologic Treatment of Pediatric Hypertension." In Pediatric Hypertension, 421–27. Totowa, NJ: Humana Press, 2004. http://dx.doi.org/10.1007/978-1-59259-797-0_24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Hypertension – Treatment"

1

Wilson, J., M. A. Orchard, A. A. Spencer, J. A. Davies, and C. R. M. Prentice. "TREATMENT OF RAISED BLOOD PRESSURE WITH NISOLDIPINE REDUCES "SPONTANEOUS" PLATELET AGGREGATION IN WHOLE BLOOD." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644260.

Full text

Abstract:

Hypertensive patients are at risk of premature vascular disease, and abnormalplatelet function in hypertensive subjects may contribute to vascular damage. Ina placebo controlled, double blind, cross over study, we have investigated theeffect of treatment of moderate hypertension with nisoldipine (a 1,4, dihydropyridine calcium antagonist) on several aspects of platelet function. In 12 hypertensive subjects, venous blood samples were taken for platelet count, PCV, βTG, PF4, and aggregation to standard doses of ADP and adrenaline in whole blood. Platelet aggregation in whole blood which occurred during processing (spontaneous aggregation) was also recorded. Samples were collected on four occasions: after 4 weeks treatment with placebo (A), after 6 weeks and 12 weeks of the crossover phase with either nisoldipine (B) or placebo (C), and finally after re-establishment of blood pressure control on routine therapy (D). Nisoldipine was effective in lowering blood pressure, with mean values during the 4 treatment phases of: A 119 mmHg, B 104 mmHg (p < 0.01), C 114 mnHg, D 103 mmHg. Neither nisoldipine nor routine treatment significantly affected platelet count, PCV, βTG, PF4 or aggregation in whole blood to adrenalin or ADP. "Spontaneous aggregation" in whole blood however, was significantly inhibited by reduction in blood pressure during treatment both with nisoldipine and routine drugs. Treatment of hypertension appears to raise the threshold of blood platelets for aggregation regardless of the pharmacological agent used.

APA, Harvard, Vancouver, ISO, and other styles

2

Peter, Dinesh A., Yared Alemu, Michalis Xenos, Ori Weisberg, Itzik Avnery, and Danny Bluestein. "Fluid Structure Interaction (FSI) Methodology for Evaluation of a Passive Endovascular Carotid Implant for Hypertension Treatment." In ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53298.

Full text

Abstract:

Drug-resistant hypertensive patients may be treated by stimulating baroreceptors located in the arterial walls of the internal carotid artery, specifically in the sinus region of the carotid artery bifurcation. To assess the ability of a custom implant design to stimulate baroreceptors by triggering them to fire and thereby reduce hypertension, the design was deployed within a patient based carotid bifurcation and FSI simulations were conducted. Results demonstrate the effect of such an implant on the arterial wall region where the baroreceptors are located. Localized wall contact and pulsatile stretch due to the implant are depicted by elevated wall stresses in the corresponding regions. These FSI simulations indicate that such a device would trigger baroreceptor firing and thus may effectively reduce hypertension in patients who do not respond to medication.

APA, Harvard, Vancouver, ISO, and other styles

3

Thipsawet, Pornprasert, Nattapong Kaewboonma, and Puriwat Lertkrai. "Hypertension management ontology based on Thai guidelines on the treatment of hypertension." In PROCEEDINGS OF THE 3RD INTERNATIONAL CONFERENCE ON APPLIED SCIENCE AND TECHNOLOGY (ICAST’18). Author(s), 2018. http://dx.doi.org/10.1063/1.5055548.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Browne, Emma, Carlos Echevarria, James Lordan, Andrew Fisher, Guy MacGowan, Gareth Parry, Rachael Crackett, Margaret Day, Julia DeSoyza, and Paul Corris. "Medical Treatment Of Chronic Thromboembolic Pulmonary Hypertension." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a1951.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Sandi, Gitarja, Suhono Harso Supangkat, and Cepy Slamet. "Health risk prediction for treatment of hypertension." In 2016 4th International Conference on Cyber and IT Service Management. IEEE, 2016. http://dx.doi.org/10.1109/citsm.2016.7577584.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

RODRIGUES, PATRICK FONTES, LUIZ PIERRE HUNING, ANA PAULA ADAME, and MARCIO AUGUSTO NOGUEIRA. "ENTEROPATHIC SPONDYLITIS: TREATMENT, PANCYTOPENIA AND PORTAL HYPERTENSION IDIOPATHIC." In 36º Congresso Brasileiro de Reumatologia. São Paulo: Editora Blucher, 2019. http://dx.doi.org/10.5151/sbr2019-092.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Киреева, Виктория, Viktoriya Kireeva, Г. Лифшиц, G. Lifshic, Н. Кох, N. Koh, Ю. Усольцев, Yu Usolcev, Константин Апарцин, and Konstantin Apartsin. "Advantages of a personalized approach to the prevention and treatment of cardiovascular diseases in the staff of the INC Of the SBRAS." In Topical issues of translational medicine: a collection of articles dedicated to the 5th anniversary of the day The creation of a department for biomedical research and technology of the Irkutsk Scientific Center Siberian Branch of RAS. Москва: INFRA-M Academic Publishing LLC., 2017. http://dx.doi.org/10.12737/conferencearticle_58be81ec9ed47.

Full text

Abstract:

Purpose of the study. To test the functional associations of polymorphic variants of genes in the regulation of blood pressure and vascular tone in employees of the ISC SB RAS. Materials and methods. The study involved patients, employees of the ISC SB RAS, being under care of the outpatient clinic of the Hospital of the ISC SB RAS. During routine laboratory testing the patients were taken 2 ml of blood for genetic analysis and further molecular genetic study on “Hypertension”, “Endothelial dysfunction”, “Pharmacogenetics”, “Inflammatory response” panels. Results. In the analysis of 12 genes coding for key proteins of hormonal enzyme blood pressure regulation systems, polymorphism of CYP11B2 showed statistically significant correlation with the presence of arterial hypertension, which makes its further study promising. The presence of allele C showed protective significance in relation to the development of hypertension with OR = 0,247. When checking associations of functional polymorphic variants of genes, the products of which are involved in the regulation of vascular tone, with hypertension in patients younger than 50 years old we found association of T/T rs5443GNB3 genotype with the debut of hypertensive disease under the age of 50. The data obtained allow the doctor to choose the most personalized and effective safe drug from certain groups, as well as its dose for employees having passed molecular genetic testing. These data can reveal predisposition to the most widespread and socially significant diseases in the surveyed subjects and provide specific personalized recommendations for the prevention of these diseases.

APA, Harvard, Vancouver, ISO, and other styles

8

Hemnes, Anna R., Meredith E. Pugh, Alexander L. Newman, Ivan Robbins, James Tolle, Eric D. Austin, and John H. Newman. "End Tidal Carbon Dioxide: Pulmonary Arterial Hypertension Versus Pulmonary Venous Hypertension And Response To Treatment." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a2012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Walia, Sheenam, Gd Puri, Komal Gandhi, Mk Ganesh, and Banashree Mandal. "Outcomes of surgical treatment of VSD with pulmonary hypertension." In ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.oa1638.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Onishi, Hiroyuki, Yu Taniguchi, Yoichiro Matsuoka, Yu Izawa, Yasunori Tsuboi, Hiromasa Otake, Seimi Satomi-Kobayashi, Noriaki Emoto, and Ken-Ichi Hirata. "Interventional Treatment in Chronic Thromboembolic Pulmonary Hypertension with Microvasculopathy." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.3452.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Hypertension – Treatment"

1

Fair, M. D. Increasing the treatment of hypertension through primary intervention. Office of Scientific and Technical Information (OSTI), December 1994. http://dx.doi.org/10.2172/121304.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Rhodes, David B., and Brian Howe. Lisinopril for the Treatment of Hypertension in Aviators. Fort Belvoir, VA: Defense Technical Information Center, February 1999. http://dx.doi.org/10.21236/ada361212.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Xin, Liu, He Haiying, Wu Haihuan, and Xin Yuemei. Meta analysis of milrinone in the treatment of persistent pulmonary hypertension in newborns. International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2020. http://dx.doi.org/10.37766/inplasy2020.5.0014.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Molatore, Thomas. A comparison of the effects of biofeedback and meditation treatment on essential hypertension. Portland State University Library, January 2000. http://dx.doi.org/10.15760/etd.2930.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

FEDOTKINA, S. A., O. V. MUZALEVA, and E. V. KHUGAEVA. RETROSPECTIVE ANALYSIS OF THE USE OF TELEMEDICINE TECHNOLOGIES FOR THE PREVENTION, DIAGNOSIS AND TREATMENT OF HYPERTENSION. Science and Innovation Center Publishing House, 2021. http://dx.doi.org/10.12731/978-0-615-67320-2-4-22.

Full text

Abstract:

Introduction. The economic losses associated with disability due to diseases of the circulatory system, as well as the costs of providing medical care to patients suffering from heart and vascular diseases, are increasing annually. The state preventive measures currently being carried out are of a delayed nature. The results of the medical examination of the population of the Russian Federation in recent years (2015-2019) indicate that the incidence of cardiovascular diseases, including hypertension, is at a fairly high level. In the middle of the last century, the Concept of risk factors for the development of chronic non-communicable diseases were formulated, in the structure of which cardiovascular diseases, including arterial hypertension, occupies one of the primary positions. The concept is based on the results of promising epidemiological studies, and, at present, is a methodological basis for planning and organizing primary prevention of cardiovascular diseases. The purpose of the study. Based on the analysis of literary sources (including foreign ones) containing experience in the use of telemedicine technologies, to assess their significance for the prevention, diagnosis and treatment of hypertension, as well as forecasting improvements in the quality of medical care when adapting to the use of clinical recommendations. Materials and methods. The article provides an analytical review of the use of modern telemedicine technologies in the prevention of hypertension. The results of the study and their discussion. The analysis of literary sources has shown that in the context of the progress of information and telecommunication technologies in the healthcare system, a fundamentally new direction has appeared in the organization and provision of medical care to the population - telemedicine, which will ensure the modern level of prevention, detection and treatment of chronic non-communicable diseases, and also determines positive medical, social and economic performance indicators. To date, updates in the legislative framework of the Russian Federation are aimed at ensuring that medical care with the use of telemedicine technologies is more widespread, taking into account the standards of medical care and clinical recommendations. Conclusion. Based on a review of literature sources, it has been established that the modern solution to the problem of improving the quality of medical care for patients, including those with hypertension, diseases is medical care using telemedicine technologies that prove their medical, social and economic effectiveness.

APA, Harvard, Vancouver, ISO, and other styles

6

Xin, Yuning, Hongyu Li, Gungyu Cheng, Junfeng Cui, Yinghui Liu, Aidong Liu, Xiaolin Xu, Pengfei Li, and Huize Han. Evaluation of the Effectiveness and Safety of Acupuncture in the Treatment of Cervicogenic Hypertension A Protocol for Systematic Review and Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2022. http://dx.doi.org/10.37766/inplasy2022.12.0036.

Full text

Abstract:

Review question / Objective: The purpose of this study is to explore the efficacy and safety of acupuncture in the treatment of patients with cervicogenic hypertension，Through scientific verification, it provides clinicians with application reference and provides more choices for patients to solve pain. Patients included should have a clear diagnosis of cervicogenic hypertension(In the absence of antihypertensive drugs, blood pressure was measured 3 times a day, systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg; or a clear history of hypertension and Diagnosis of cervical spondylosis using computed tomography, magnetic resonance imaging, and other imaging methods)；The intervention group received acupuncture treatment alone or acupuncture combined with treatment by Chinese herbal medicine or conventional Western medicine; The control group was a blank control group, a placebo group, a fake acupuncture group or received treatment only through conventional Western medicine； The Inclusion criteria of study type was an RCT; The outcomes of the main analyses were efficacy of clinical symptoms，systolic blood pressure value，Diastolic blood pressure value；Secondary outcome indicators were Traditional Chinese Medicine syndrome curative effects, Traditional Chinese Medicine syndrome scores,and adverse reactions.

APA, Harvard, Vancouver, ISO, and other styles

7

MOSKALENKO, O. G., and R. A. YASKEVICH. FACTORS AFFECTING THE QUALITY OF LIFE IN PATIENTS WITH ARTERIAL HYPERTENSION (LITERATURE REVIEW). Science and Innovation Center Publishing House, April 2022. http://dx.doi.org/10.12731/2658-4034-2022-13-1-2-136-143.

Full text

Abstract:

A review of the literature on the actual problem of medicine - the factors influencing the decrease in the quality of life associated with health in patients with arterial hypertension presented. The study of QOL and the factors affecting it can contribute to an increase in the individual effectiveness of treatment and comprehensive rehabilitation of patients with hypertension.

APA, Harvard, Vancouver, ISO, and other styles

8

MOSKALENKO, OLGA, and ROMAN YASKEVICH. QUALITY OF LIFE ASSESSMENT IN PATIENTS WITH ARTERIAL HYPERTENSION (LITERATURE REVIEW). Science and Innovation Center Publishing House, March 2021. http://dx.doi.org/10.12731/2658-4034-2021-12-1-2-178-184.

Full text

Abstract:

A review of the literature on the current problem of medicine is presented. Arterial hypertension is one of the common chronic diseases for which the current goal of therapy is not recovery, but improvement of circulatory function with a satisfactory quality of life. The study of QOL and the factors influencing it can contribute to an increase in the individual effectiveness of treatment and complex rehabilitation of patients suffering from this pathology.

APA, Harvard, Vancouver, ISO, and other styles

9

Li, Jiaxin, Yanwei Hao, Shaofeng Wang, Wei Li, Shengnan Yue, Qingsong Liu, and Bin Li. Evaluation of Songling Xuemaikang Capsule in the treatment of essential hypertension: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0126.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Chaparadza, Diana. An Analysis of Patient-Generated Health Data in Assisting Nurses and Physicians to Better Treat Patients with Hypertension. University of Tennessee Health Science Center, November 2020. http://dx.doi.org/10.21007/chp.hiim.0080.

Full text

Abstract:

Patient Generated Health Data (PGHD is not new but it has gained more attention these past years due to the advent of smart devices, remote monitoring devices and many applications on various smart devices. PGHD reflects medications and treatment, lifestyle choices, and health history. Unlike traditional medical visits, where clinicians collect and manage data within their offices, PGHD is collected by patients throughout the course of their day and provides an insight of how they are responding to treatments or lifestyle choices. Examples include blood glucose monitoring or blood pressure readings using home health equipment, exercise and diet tracking using mobile applications or wearable devices such as the Fitbit or other smart watches.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!